Committed to
Treatments and Cures of ​
Alzheimer’s Disease,Bipolar Disorder,Major Depressive Disorder,Post-traumatic Stress Disorder

SCROLL

Alzamend Neuro, Inc.

Committed to Treatments and Cures of Alzheimer’s Disease, Bipolar Disorder, Major Depressive Disorder and Post-traumatic Stress Disorder

Alzamend Neuro® is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

×

We are driven by the belief that strong support of research is the foundation for true innovation.

Publications

Recently Published Articles

Statistics

6.5 million
The number of Americans projected currently living with Alzheimer’s disease in 2022
7 million
The number of Americans projected currently living with Bipolar disorder in 2022
9 million
The number of Americans projected currently living with PTSD in 2022
21 million
The number of Americans projected currently living with MDD in 2022
43.5 million
The number of Americans that can potentially benefit from AL001 in 2022
664 million
The potential global patient population for AL001 in 2022
Previous
Next